Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C - Fig 6

<p><b>Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 9 female patients without a SVR.</b> PT: post-treatment. *, <i>P</i> < 0.05; **, <i>P</i> < 0.01.</p

Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C - Fig 2

<p><b>Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 15 patients without a SVR.</b> PT: post-treatment. *, <i>P</i> < 0.05; **, <i>P</i> < 0.01; ***, <i>P</i> < 0.001.</p

Baseline characteristics of 159 patients with chronic hepatitis C.

<p>Baseline characteristics of 159 patients with chronic hepatitis C.</p

Baseline characteristics of 80 female patients with a SVR and 9 without.

<p>Baseline characteristics of 80 female patients with a SVR and 9 without.</p

Baseline characteristics of 144 patients with a SVR and 15 without.

<p>Baseline characteristics of 144 patients with a SVR and 15 without.</p

Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C - Fig 4

<p><b>Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 80 female patients with a SVR.</b> PT: post-treatment. **, <i>P</i> < 0.01; ***, <i>P</i> < 0.001.</p

Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C - Fig 7

<p><b>Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 48 patients with ALT < 30 U/L who achieved a SVR.</b> PT: post-treatment. *, <i>P</i> < 0.05; **, <i>P</i> < 0.01; ***, <i>P</i> < 0.001.</p

Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C - Fig 3

<p><b>Changes in serum levels of (A) HCV RNA, (B) ALT, (C) ATX, (D) FIB-4 index, and (E) APRI before, during, and after IFN-DAA therapy in 64 male patients with a SVR.</b> PT: post-treatment. **, <i>P</i> < 0.01; ***, <i>P</i> < 0.001.</p

Serial changes in HCV RNA, ALT, ATX, FIB-4 index, and APRI in representative patients with ALT < 30 U/L who were treated with IFN-free DAA therapy.

<p>(A) A 71-year-old man was treated with ledipasvir + sofosbuvir for 12 weeks. He achieved a SVR. (B) An 82-year-old man was treated with ledipasvir + sofosbuvir for 12 weeks. He was considered a relapser because HCV RNA was undetectable at 4 weeks of treatment but became positive afterwards. PT: post-treatment.</p

Baseline characteristics of 48 patients with ALT < 30 U/L and a SVR and 6 without.

<p>Baseline characteristics of 48 patients with ALT < 30 U/L and a SVR and 6 without.</p